Allogene Therapeutics
South San Francisco
CA
United States
194 articles about Allogene Therapeutics
-
Allogene Therapeutics Appoints Geoffrey Parker as Chief Financial Officer
10/16/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer.
-
Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
9/27/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced three preclinical poster presentations at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 1-5, 2023, in San Diego, CA.
-
Allogene Therapeutics Announces Participation in September Investor Conference
9/5/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in an upcoming investor conference in September.
-
Allogene Therapeutics Appoints Earl Douglas as General Counsel
8/14/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that Earl Douglas has been appointed as General Counsel.
-
Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update
8/2/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, provided a corporate update and reported financial results for the quarter ended June 30, 2023.
-
Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023
7/26/2023
Allogene Therapeutics, Inc. today announced that it will report second quarter 2023 financial results on Wednesday, August 2, 2023, after the close of the market.
-
Allogene Therapeutics Provides Additional ALLO-501/501A Phase 1 Data in an Oral Presentation at the International Conference on Malignant Lymphoma (ICML) Lugano
6/15/2023
Allogene Therapeutics, Inc. at the International Conference on Malignant Lymphoma in Lugano, Switzerland presented updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in 33 CAR T naïve patients with relapsed/refractory large B-cell lymphoma treated with the Alloy™ manufacturing process material across different CAR T dosing and lymphodepletion regimens.
-
Allogene Therapeutics Announces Departure of Chief Financial Officer
6/14/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that its Chief Financial Officer, Eric T. Schmidt, Ph.D., will step down from his position to spend more time with his family on the East Coast.
-
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-501/501A in Large B Cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) Lugano
6/9/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced it will present data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL) in an oral presentation at the International Conference on Malignant Lymphoma (ICML) on June 13–17, 2023.
-
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
6/3/2023
Allogene Therapeutics, Inc. presented long-term follow up data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A in patients with relapsed/refractory large B-cell lymphoma at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois.
-
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences - May 24, 2023
5/24/2023
Allogene Therapeutics, Inc. today announced that it will participate in three upcoming investor conferences.
-
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
5/11/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced an encore presentation of data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the European Hematology Association (EHA) Hybrid Congress on June 8–11, 2023 in Frankfurt, Germany.
-
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
5/3/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, provided a corporate update and reported financial results for the quarter ended March 31, 2023.
-
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
4/26/2023
Allogene Therapeutics, Inc. today announced it will present updated data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2 – 6, 2023 in Chicago, Illinois.
-
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
4/25/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report first quarter 2023 financial results on Wednesday, May 3, 2023, after the close of the market.
-
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
4/20/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced the appointment of Timothy Moore to Executive Vice President, Chief Technical Officer effective April 24, 2023.
-
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
4/17/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today presented interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR TTM investigational product candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
-
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
4/13/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, announced that it will participate in four upcoming investor conferences.
-
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
3/30/2023
Allogene Therapeutics, Inc., a clinical-stage biotechnology company pioneering the development of allogeneic CAR T products for cancer, published its 2022 annual ESG report.
-
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
3/14/2023
Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced that it will present interim data from its Phase 1 TRAVERSE trial of ALLO-316, the Company’s first AlloCAR T candidate for solid tumors, in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting taking place in April in Orlando, Florida.